Biomechanics Laboratory, III Clinic, Rizzoli Orthopaedic Institute, Via Di Barbiano, 1/10, 40136, Bologna, Italy.
Knee Surg Sports Traumatol Arthrosc. 2013 Aug;21(8):1717-29. doi: 10.1007/s00167-012-2329-3. Epub 2013 Jan 11.
The aim of this systematic review is to examine the available clinical evidence in the literature to support mesenchymal stem cell (MSC) treatment strategies in orthopaedics for cartilage defect regeneration.
The research was performed on the PubMed database considering the English literature from 2002 and using the following key words: cartilage, cartilage repair, mesenchymal stem cells, MSCs, bone marrow concentrate (BMC), bone marrow-derived mesenchymal stem cells, bone marrow stromal cells, adipose-derived mesenchymal stem cells, and synovial-derived mesenchymal stem cells.
The systematic research showed an increasing number of published studies on this topic over time and identified 72 preclinical papers and 18 clinical trials. Among the 18 clinical trials identified focusing on cartilage regeneration, none were randomized, five were comparative, six were case series, and seven were case reports; two concerned the use of adipose-derived MSCs, five the use of BMC, and 11 the use of bone marrow-derived MSCs, with preliminary interesting findings ranging from focal chondral defects to articular osteoarthritis degeneration.
Despite the growing interest in this biological approach for cartilage regeneration, knowledge on this topic is still preliminary, as shown by the prevalence of preclinical studies and the presence of low-quality clinical studies. Many aspects have to be optimized, and randomized controlled trials are needed to support the potential of this biological treatment for cartilage repair and to evaluate advantages and disadvantages with respect to the available treatments.
IV.
本系统评价旨在研究文献中现有的临床证据,以支持间充质干细胞(MSC)在骨科软骨缺损再生中的治疗策略。
在 PubMed 数据库中以 2002 年为时间节点,使用英文文献进行研究,检索词包括软骨、软骨修复、间充质干细胞、MSC、骨髓浓缩物(BMC)、骨髓间充质干细胞、骨髓基质细胞、脂肪间充质干细胞和滑液间充质干细胞。
系统研究表明,随着时间的推移,关于该主题的发表研究数量不断增加,共确定了 72 篇临床前论文和 18 项临床试验。在确定的 18 项聚焦于软骨再生的临床试验中,没有随机试验,5 项为对照试验,6 项为病例系列研究,7 项为病例报告;其中 2 项涉及脂肪间充质干细胞的应用,5 项涉及 BMC,11 项涉及骨髓间充质干细胞,初步研究结果从局灶性软骨缺损到关节骨关节炎退变不等。
尽管人们对这种用于软骨再生的生物方法越来越感兴趣,但正如临床前研究的普遍存在和低质量临床研究的存在所表明的那样,该领域的知识仍然处于初步阶段。许多方面需要进一步优化,需要进行随机对照试验以支持这种生物治疗在软骨修复中的潜力,并评估其与现有治疗方法相比的优缺点。
IV。